Har­bour Bio­Med fol­lows can­cer drug deals with a hefty $85M Se­ries B backed by Sin­ga­pore's GIC

Rid­ing on the mo­men­tum of two li­cens­ing deals, Har­bour Bio­Med now has $85 mil­lion to ad­vance its fresh­ly beefed up pipeline.

GIC — Sin­ga­pore’s sov­er­eign wealth fund — led the Se­ries B, lead­ing a syn­di­cate that in­cludes Chi­na Life Pri­vate Eq­ui­ty In­vest­ment and Ver­tex Ven­tures as well as Se­ries A in­vestors Ad­van­Tech and Leg­end Cap­i­tal.

Founder and CEO Jing­song Wang calls the round a “strong vote of con­fi­dence” for the Chi­nese biotech’s three-pronged strat­e­gy built around its foun­da­tion­al hu­man trans­genic an­ti­body tech­nol­o­gy, dubbed Har­bour Mice: out-li­cens­ing its tech, in-li­cens­ing as­sets to de­vel­op on the plat­form and dis­cov­er­ing new ones in-house.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER